Related Experiment Video
Updated: Aug 23, 2026

A Genetically Engineered Mouse Model of Sporadic Colorectal Cancer
Published on: July 6, 2017
Wip1-deficient mice are resistant to common cancer genes
Martin Harrison1, Jing Li, Yan Degenhardt
1Tularik Ltd, Aleutian House, Tytherington Business Park, Macclesfield, Cheshire SK19 2XR, UK.
Abstract:
PPM1D encodes WIP1, a serine-threonine phosphatase that had previously been shown to be the driver oncogene of a 17q23 amplicon that is present in approximately 15% of human breast tumors. However, it is unknown whether it has any role in the remaining 85% of breast tumors. A recent study using Wip1-deficient mice revealed that blocking its function significantly impaired RAS and ERBB2-induced breast tumor formation, suggesting that the inhibition of Wip1 could be a broad-spectrum treatment for breast cancer. However, because of the structure of Wip1, the development of small molecule inhibitors is a significant challenge.
Insights
WIP1 phosphatase is a key driver in some breast cancers. Inhibiting WIP1 shows promise as a broad-spectrum breast cancer treatment, despite challenges in developing inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The PPM1D gene encodes WIP1, a serine-threonine phosphatase.
- WIP1 is an oncogene associated with a 17q23 amplicon in ~15% of breast tumors.
- Its role in the remaining 85% of breast cancers is largely unknown.
Purpose of the Study:
- To investigate the role of WIP1 in breast tumor formation beyond known amplicon-associated cases.
- To explore the therapeutic potential of targeting WIP1 in breast cancer.
Main Methods:
- Utilized Wip1-deficient mouse models.
- Investigated the impact of WIP1 function blockade on RAS and ERBB2-induced breast tumorigenesis.
Main Results:
- WIP1 deficiency significantly impaired RAS and ERBB2-driven breast tumor formation in mice.
- This suggests WIP1 plays a crucial role in a broader spectrum of breast cancers.
Conclusions:
- WIP1 inhibition represents a potential broad-spectrum therapeutic strategy for breast cancer.
- The complex structure of WIP1 presents challenges for small molecule inhibitor development.
More Related Videos
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects (TEdeff) in Cancers
Published on: September 26, 2019
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Related Concept Videos
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
In-vitro Mutagenesis
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Treatment Resistant Cancers